GSR Ventures led the round with participation from Sequoia Capital, Storm Ventures, NextGen Venture Partners and BIXINK Therapeutics.
The new funding enables further research and development of the company’s flagship product, Limbix Spark, the first prescription digital therapeutic designed to treat adolescents with depression.
Welcome to #TheNextWave, a conversation series with the Headstream Accelerator Finalists who want to use social tech for the good of humanity.
This year's cohort includes 27 companies that are working on everything from digital therapeutics to care coordination tools, to clinician workflow platforms, to opioid alternatives.
Clinical study tech company TrialSpark teamed up with digital mental health firm Limbix to work on a new “digital therapeutic” for adolescent depression.
For media inquiries and our press kit, please contact firstname.lastname@example.org
Digital therapeutics for adolescent mental health